Dr
Alisha Chakrabarti
(James P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America; Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.)
Introduction: Cancer survivors experience many symptoms years after treatment. This overall symptom burden interferes significantly with the ability to work and perform activities of daily living (ADLs). Yoga, a form of exercise, is a promising therapy to mitigate these symptoms.
Methods: We conducted a nationwide, multicenter, phase III, RCT testing the effect of Yoga for Cancer Survivors (YOCAS©®) on overall symptom burden (OSB) and OSB interference (OSBi) with work and ADLs. Cancer survivors, 2-24 months posttreatment were recruited via the University of Rochester Cancer Center (URCC) National Cancer Institute Community Oncology Research Program (NCORP) Research Base across the United States. Survivors were randomized to the YOCAS©® yoga intervention (10-15 survivors/group; 75 minutes/session; 2x/week; 4 weeks; gentle Hatha and Restorative) or usual care. OSB and OSBi with work and ADLs were assessed at baseline and post intervention, using a Clinical Symptom Inventory.
Results: A total of 410 cancer survivors; 96% female, mean age 54 years, 75% breast cancer survivors were recruited. Mixed effects modeling demonstrated that YOCAS©® participants experienced a significant reduction in OSB compared to usual care participants (mean change difference [MCD]-5.64, SE=1.16, p<0.05) from pre- to post-intervention. YOCAS©® participants reported significant reductions in OSB from pre- to post-intervention (mean change [MC]-6.64, SE=0.93, p<0.05), while usual care participants did not (MC-0.96, SE=0.87, p>0.05). YOCAS©® participants also experienced significant reductions in OSBi with work (MCD-0.86, SE=0.23, p<0.05) and ADLs (MCD-1.01, SE=0.22, p<0.05) compared to usual care participants. YOCAS©® participants reported significant reductions in OSBi with work (MC-0.97, SE=0.19, p<0.05) and ADLs (MC-1.02, SE=0.19, p<0.05), pre- to post-intervention, while usual care participants did not (work MC-0.04, SE=0.18; and ADLs MC=0.21, SE=0.18, all p>0.05).
Conclusion: YOCAS©® yoga is effective for reducing OSB and OSBi with work and ADLs among cancer survivors. Further research is needed to confirm these results.
Funding: NCI UG1CA189961, T32CA102618
Keywords
symptom burden, activities of daily living, cancer survivors, yoga
| Abstract submitters declaration |
yes
|
| Conflict of Interest & Ethical Approval |
yes
|
Dr
Alisha Chakrabarti
(James P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America; Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.)
Dr
Po-Ju Lin
(James P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America; Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.)
Lindsey Mattick
(James P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America; Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.)
Umang Gada
(James P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America; Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.)
Yuri Choi
(James P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America; Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.)
Brittany LaVaute
(James P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America; Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.)
Adam Szczupakowski
(James P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America; Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.)
Marcus Palvino
(James P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America; Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.)
Cheyenne Wilson
(James P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America; Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.)
Carla Jorgensen
(NCORP of the Carolinas-Prisma Health NCORP/Greenville, Greenville, South Carolina, United States of America.)
Christopher Chay
(Southeast Clinical Oncology Research Consortium (SCOR), Winston Salem, North Carolina, United States of America)
Janet Ruzich
(Pacific Cancer Research Consortium (PCRC), Oregon City, Oregon, United States of America)
Karen Mustian
(James P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America; Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.)
There are no materials yet.
